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SolubilityDrug repositioning is defined as a process to identify a new application for drugs. This approach is critical
as it takes advantage of well-known pharmacokinetics, pharmacodynamics, and toxicity profiles of the
drugs; thus, the chance of their future failure decreases, and the cost of their development and the
required time for their approval are reduced. Anthelmintics, which are antiparasitic drugs, have recently
demonstrated promising anticancer effects in vitro and in vivo. This literature review focuses on the
potential of anthelmintics for repositioning in the treatment of cancers. It also discusses their pharma-
cokinetics and pharmacodynamics as antiparasitic drugs, proposed anticancer mechanisms, present
development conditions, challenges in cancer therapy, and strategies to overcome these challenges.
 2021 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access
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Cancer, with rapidly increasing incidence (18.1 million new
cases and annual incidence of 3–5%, 2018) and mortality (9.6 mil-
lion patients, 2018), is one of the most critical health issues
throughout the world (Hassankhani, Rahmani, Taleghani, Sanaat,
& Dehghannezhad, 2020; J. Zhang et al., 2019). Many efforts have
been made to develop anti-cancer agents, and various lead candi-
dates have been developed at preclinical and clinical stages; how-
ever, only 5% of compounds that enter phase I clinical trials receive
the end approval (Kato et al., 2015).
Generally, to develop a novel anti-neoplastic agent, various
natural-based compounds derived from microorganisms, animals,
and plants are evaluated by a variety of pharmacological and bio-
chemical analyses, that often continue with the whole chemical
synthesis or modification of determined individual compounds
(Čáňová, Rozkydalová, & Rudolf, 2017). Further, this process of
drug development has been complemented by screening the
assays of libraries of all recognized and determined compounds
to select the potentially appropriate candidates for further
assessment. However, these strategies are associated with several
difficulties, such as financial burden, laboriousness, and longer
duration for drug development (Čáňová et al., 2017). Currently,
the development of a new drug takes 10–15 years, and the success
rate is negligible (approximately 2%). As the cost of clinical trials
has recently increased, the number of new drugs, approved by
Food and Drug Administration (FDA) has been decreased (Laudisi,
Marônek, Di Grazia, Monteleone, & Stolfi, 2020; Scannell,
Blanckley, Boldon, & Warrington, 2012). Between 2004 and 2012,
on average 2–3 billion US dollars were spent for a pharmaceutical
clinical trial, and considering the inflation, this value would be
higher now (Sertkaya, Wong, Jessup, & Beleche, 2016). Companies
have recently claimed that developing new drugs is unfavorable
and risky (Laudisi et al., 2020); therefore, new strategies are
required to optimize the development of novel and efficacious
anti-neoplastic agents. One of the favorite strategies is drug
repositioning (or repurposing) (Čáňová et al., 2017).
Drug repositioning is a process by which a new application
for an existing drug can be provided (Yaseen & Akram, 2019).
This is a promising approach since many existing drugs are
developed by standardized constructing techniques and have
well-known pharmacokinetics, pharmacodynamics, and toxicity
profiles; therefore, the chance of their future failure decreases
owing to their adverse effects. Also, the cost of the development
of a repositioned drug (50–60% compared to new drugs) and the
required time (3–12 years) for its approval are reduced
(Armando, Mengual Gómez, & Gomez, 2020; Čáňová et al.,
2017). In addition, while approximately 10% of new drug appli-
cations reach the market, this value for repositioned drugs is
approximately 30%, encouraging pharmaceutical companies to
reposition the existing assets (Ashburn & Thor, 2004). Currently,435more than 270 drugs are being assessed for their potential anti-
tumor activity (Armando et al., 2020), and from these, approxi-
mately 57% have demonstrated anti-tumor effects in human clin-
ical trials (Xue, Li, Xie, & Wang, 2018). One of the important
groups of drugs, which have demonstrated anti-tumor activity,
is anthelmintic agents.
Anthelmintics are a series of compounds, demonstrating anti-
infectious activity against helminths, which settle in the human
intestine (Laudisi et al., 2020). These therapeutics were initially
developed for the treatment of veterinary parasites and have sub-
sequently been used for patients, suffering from helminthiasis.
Anthelmintics have a variety of chemical entities and function
through changing the parasite (worm) metabolism or paralyzing
the parasite, in which the parasite can be eliminated by the host
immune system (Laudisi et al., 2020; Rajagopal et al., 2019). It
has been demonstrated that some of the anthelmintics are able
to inhibit critical oncogenic pathways, such as Wnt/b-catenin, sig-
nal transducer and activator of transcription proteins 3 (STAT3),
and nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-jB) (Laudisi et al., 2020); therefore, their application for cancer
treatment has been considered.
This literature review provides an overview of the updated
information about anthelmintics with anti-cancer activity and
their possible use as anti-cancer agents (i.e., repositioned drugs).
These anthelmintics are characterized, in terms of their i) struc-
tural analysis, ii) tumor type-specific effects, iii) mode of action,
and iv) up to date data about the clinical trials. It also discusses
the challenges for their applications as anti-cancer agents, such
as low water solubility and low bioavailability, and strategies to
overcome these challenges, such as nanocarrier-based formula-
tions, pro-drug formulations, and solid dispersions (SDs).2. Physicochemical properties of anthelmintics
2.1. Pharmacokinetics and pharmacodynamic
According to chemical structures and pharmacological proper-
ties, there are seven classes of modern anthelmintics, including
benzimidazoles (BZDs; cambendazole, parbendazole, thiabenda-
zole, mebendazole, fenbendazole, oxfendazole, oxibendazole,
albendazole, ricobendazole, and triclabendazole), pro-
benzimidazoles (pro-BZDs; netobimin, febantel, and thiophanate),
tetrahydropyrimidines (THPs; pyrantel pamoate, pyrantel tartrate,
andmorantel), imidazothiazoles (IMTs; levamisole), iso-quinolines,
salicylanilides (closantel, niclosamide, and rafoxanide), and macro-
cyclic lactones (MLs, avermectins and milbemycins or endecto-
cides; ivermectin, abamectin, moxidectin, doramectin,
eprinomectin, selamectin, and milbemycin oxime) (Barbosa,
Löbenberg, de Araujo, & Bou-Chacra, 2019; Gokbulut & McKellar,
2018).
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tion, distribution, and biotransformation/elimination pattern, are
critical factors, which determine the time to a maximum effect-
site concentration of the drugs (anti-parasitic) in the body. Phar-
macokinetics, as a determinant factor for drug exposure in the par-
asitic location, are strongly correlated with pharmacodynamics
(drug effect) (Lanusse et al., 2018). Anthelmintics are administered
by oral drench (as a general route), slow-release bolus, injection, or
in-feed (Taylor, 1999).
According to previous studies (Davis et al., 2020; Lalthanpuii &
Lalchhandama, 2020), transcuticular/tegumental diffusion is an
appropriate route for drug entrance into parasitic worms. Drug
entrance into the parasite is determined by drug lipophilicity, as
a critical physicochemical factor, in which by increasing the drug
lipophilicity, a higher amount of the drug can be penetrated and
consequently accumulated within the parasite (Lifschitz, Lanusse,
& Alvarez, 2017). Therefore, drug entrance and accumulation into
a parasitic worm are crucial factors to achieve the optimal thera-
peutic outcome. Also, other factors, such as i) the balance among
drug entry (influx), ii) the capacity of the parasite to metabolize
and inactivate the drug, and iii) the drug efflux capacity of the par-
asite, determine the drug accumulation within a parasite (Lanusse,
Lifschitz, & Alvarez, 2015). The exposure time of parasite to active
drug concentrations is a critical factor that affects the efficacy and/
or durability of activity of most anthelmintics used in ruminants.
Overall, these factors are responsible to determine the ultimate
anthelmintic activity (Lanusse et al., 2018).
2.1.1. Metabolism and excretion
2.1.1.1. Benzimidazoles and Pro-benzimidazoles. Ricobendazole is
the active metabolite of albendazole and the only available inject-
able BZD. In the host body, the gastrointestinal microflora and liver
are responsible to metabolize pro-BZDs into active BZD drugs, in
which febantel, thiophanate, and netobimin are metabolized into
fenbendazole, luxabendazole, and albendazole, respectively
(Gokbulut & McKellar, 2018). BZDs are metabolized in the liver
to various molecules, such as albendazole sulfoxide and albenda-
zole sulfone for albendazole (Yang, Liu, Chen, & Zhihua, 2016).
Hydroxylation is one of the crucial metabolic pathways of BZDs.
In sheep, it has been shown that hydroxy oxfendazole and hydroxy
fenbendazole were the main hepatic metabolites of fenbendazole
following intraruminal administration that are excreted through
the bile as free or conjugated metabolites (Gokbulut & McKellar,
2018).
2.1.1.2. Imidazothiazoles and tetrahydropyrimidines. Levamisole is
metabolized in the liver and kidney into several components, such
as aminorex, and mostly excreted via the kidneys. Depending on
the animal species, it has a plasma elimination half-life of 5–6 h
(Handley, Belsey, Couchman, & Flanagan, 2019; Kolanović et al.,
2018). Pyrantel is mostly metabolized into metabolites with higher
polarity in various animals through different metabolic pathways,
including the oxidation of the thiophene ring, the oxidation of the
tetra-pyrimidine ring, and conjugation to mercapturic acid. The
polar metabolites of pyrantel are supposed to be eliminated by
the kidneys (Gokbulut & McKellar, 2018).
2.1.1.3. Macrocyclic lactones. MLs are partially metabolized by the
animal and are mainly excreted via feces (Tydén, Jansson, &
Ringmark, 2019). Ivermectin, as a member of MLs, is metabolized
in the liver by the cytochrome P450 system. The blood concentra-
tion of the drug reaches the peak 4 h after administration, and after
that, the concentration decreases slowly. The metabolites concen-
tration in the blood increases for a longer time when it is compared
with the parent compound, which can be resulted from the hetero-436hepatic recycling. The drug can be detected in various sites, includ-
ing the nodules, and subcutaneous fascia. A single oral dose
(12 mg) of ivermectin reaches the peak 8 h after administration
in various sites, such as sebum, and forehead, and starts to
decrease after 24 h (El-Saber Batiha et al., 2020).
2.1.1.4. Other anthelmintics. Closantel
Closantel is a salicylanilide compound and normally used for
veterinary purposes (Gokbulut & McKellar, 2018; Venkatesh,
Pereira, Aseem, & Yadav, 2019). It is poorly metabolized, in which
around 80% of the administered dose is eliminated through the
feces. Approximately 45% of the orally administered dose is
excreted 48 h after administration; however, this value for intra-
muscular injection is approximately 10%. Closantel has an elimina-
tion half-life of 2–3 weeks. In dairy cows, approximately 1% of the
administered dose is eliminated through the milk without any
change (Venkatesh et al., 2019).
Praziquantel
Praziquantel is an isoquinoline compound, and while in labora-
tory animals, it is metabolized to glucuronide and sulfuric conju-
gates, which are less active compared to the parent compound.
In human, the absorption of praziquantel occurs quickly and
mostly (90%) after administration and then quickly eliminated
with a plasma clearance equal to 28 L/kg (Gokbulut & McKellar,
2018).
Trichlorfon
Trichlorfon is an organophosphate that is quickly absorbed after
oral administration. It is metabolized in the liver by phosphatases
in a host species-specific manner, and the metabolites are then
eliminated through the urine (Gokbulut & McKellar, 2018).
Piperazine
Piperazine is a hexahydropyrazine compound. It is absorbed
slightly and variably from the gastrointestinal tract, and probably
the un-absorbed drug from the gastrointestinal tract is responsible
for anti-parasitic activity (Gokbulut & McKellar, 2018).3. Efficacy and spectra of activity of anthelmintics
Anthelmintics were primarily generated for the treatment of
veterinary parasites, and their application has then been expanded
for the treatment of human patients. They have a variety of chem-
ical entities and act through several modes of action. For example,
BZDs are bound selectively to b-tubulin of nematodes, cestodes,
and fluke and block the formation of microtubule and cell division
(Hamilton & Rath, 2017). Mebendazole and flubendazole, two
members of BZDs, cause the loss of cytoplasmic microtubules of
helminths, resulting in the loss of transport of secretory vesicles,
a decrease in the uptake of glucose, and an increase in the use of
stored glycogen (Hamilton & Rath, 2017). The salicylanilides drugs,
such as rafoxanide, oxyclozanide, and closantel, are proton iono-
phores (Hamilton & Rath, 2017; Hu et al., 2013) or proton carriers
to help to transfer protons from the aqueous phase into the lipo-
philic membrane (Mahmoud, Saad, Elzanfaly, Amer, & Essam,
2020). Other anthelmintics are functionally classified as nicotinic,
glutamate-gated chloride channel potentiators, or macrolides
(Hamilton & Rath, 2017).
3.1. Benzimidazoles and pro-benzimidazoles
BZDs demonstrate a significant difference, in terms of efficacy,
against various species of parasites (Gokbulut & McKellar, 2018).
In various studies, the efficacy of these drugs was evaluated against
various types of gastrointestinal nematodes, such as Strongylus
species and Parascaris species (Salem et al., 2020; Yuriadi,
Seyed Ebrahim Alavi and H. Ebrahimi Shahmabadi Saudi Pharmaceutical Journal 29 (2021) 434–445Tjahajati, Indarjulianto, & Widiyono, 2019). Yuriadi et al. (Yuriadi
et al., 2019), in one study, evaluated the efficacy of oxfendazole
(7.5 mg/kg) on a group of infected horses. The results demon-
strated that oxfendazole was completely effective (100%) to kills
Strongylus and Parascaris worms. Salem et al. (Salem et al., 2020),
in another study, investigated the efficacy of fenbendazole on the
prevalence of gastrointestinal nematode infections in working
horses to measure the resistance of strongyle to the drug using fae-
cal egg count reduction testing (FECRT). The results demonstrated
that the drug was highly potent, in which the Strongyle FECR was
found to be 100%.3.2. Imidazothiazoles and tetrahydropyrimidines
Regarding the anti-parasitic effects of pyrantel pamoate, it has
been demonstrated that this drug is a potent anthelmintic drug
against Strongylus worms (Yuriadi et al., 2019), in which an oral
dose of the drug (20 mg/kg) caused a reduction in the eggs per
gram (EPG) of feces to zero for Strongylus worms, 12 days after
administration in horses. It also demonstrated 95–97% potency
against adult cyathostomins, Parascaris equorum, and Strongylus
vulgaris, and moderate antiparasitic effects towards Strongylus
edentatus (70%) and Oxyuris equi (65%, a gastrointestinal parasite)
(Gokbulut & McKellar, 2018). Also, the oral administration of
pyrantel pamoate, as a paste formulation and at a dosage of
13.2 mg/kg, caused the parasiticidal activity of 95–98% against
mature infections of Anoplocephala perfoliata (a tapeworm in
equids) in horses and ponies (Slocombe, 2004). Hamed et al.
(Hamed, El-Allawy, & Hassnein, 2019) evaluated the anti-
parasitic potency of pyrantel (single dose, oral administration,
1 g/10 kg) in parasite-infected donkeys using EPG of feces. The
egg count was performed on days 7, 14, 21, and 28 after the drug
administration. The results demonstrated that the mean EPG% in
pyrantel treated animals was less than 90% throughout 28 days
of the treatment.3.3. Macrocyclic lactones
MLs are one of the most favorite anthelmintics, used to control
parasitic worms and arthropods of domestic animals and livestock
(Yilmaz, Gerst, McKay-Demeler, & Krücken, 2019). Of these com-
pounds, moxidectin was found significantly potent towards equine
nematodes (Gokbulut & McKellar, 2018). Katre et al. (Radha Katre,
2020) evaluated the efficacy of ivermectin and moxidectin against
gastrointestinal nematode (Strongylus species. and Parascaris spe-
cies) infection in horses using faecal egg count (FEC). The horses
received a single oral dose of ivermectin (0.2 mg/kg) and mox-
idectin (0.4 mg/kg). The results demonstrated that both the drugs
caused a reduction in the FEC for both the parasites by 100% on
the 14th-day post-treatment. However, the FEC was more rapidly
reduced in moxidectin receiver horses compared to those received
ivermectin (Radha Katre, 2020). In the other study, Shashank et al.
(Shashank & Ayodhya, 2019) evaluated the efficacy of ivermectin
against goats positive for gastrointestinal nematodal infestation
and compared the results with levamisole using the FEC method.
FEC, at day 0, was 1520 ± 156.20 and 1310 ± 126.88 in ivermectin
and levamisole receiver groups, respectively. The Strongyles, Tri-
churis, and Strongyloides species were the gastrointestinal nema-
todes that are recognized in these animals. The results of the
evaluation demonstrated that ivermectin caused a reduction of
86.22, 100 and 100% on day 3, 5 and 7 post-treatment, respectively,
in FEC, while these values for levamisole were 77.38, 97.20, and
100%, respectively. The study suggested that ivermectin could be
an ideal anthelminthic drug against both single and mixed gas-
trointestinal nematodal infestation in goats.4374. Mode of action as anti-cancer agents
Anthelmintics have exerted anti-cancer activity against various
types of cancers, in particular cancer stem cell-like subpopulations
(Hamilton & Rath, 2017). The anti-cancer activities of mebenda-
zole, pyrvinium pamoate, and niclosamide were reported by
Mukhopadhyay et al. (Mukhopadhyay, Sasaki, Ramesh, & Roth,
2002), in 2002, Esumi et al. (Esumi, Lu, Kurashima, & Hanaoka,
2004), in 2004, andWang et al. (Wang et al., 2009), in 2009, respec-
tively. Since then, several studies (Ashburn & Thor, 2004;
Pantziarka et al., 2014) have demonstrated that anthelmintics
could exert anti-cancer effects in vitro, in vivo, and in first clinical
trials. Various mechanisms, such as down-regulating the P-
glycoprotein (P-gp) expression via the inhibition of the epidermal
growth factor receptor (EGFR) (Armando et al., 2020), the disrup-
tion of microtubule polymerization, the induction of apoptosis,
inhibition of cell cycle progression (G2/M), anti-angiogenesis, the
blockage of the transport of glucose, and uncoupling the oxidative
phosphorylation in mitochondria (Barbosa et al., 2019; Son, Lee, &
Adunyah, 2020), have been identified for the anti-cancer activity of
anthelmintics (Fig. 1) (Armando et al., 2020; Son et al., 2020). Over-
all, anthelmintics can be divided into two groups; those progressed
in clinical trials (Table 1) and others that are not.4.1. Anthelmintics under clinical trials
4.1.1. Albendazole
Albendazole has demonstrated in vitro anti-tumor effect against
hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC)
and in vivo anti-tumor effect against a xenograft model of
peritoneal carcinomatosis. This drug has also shown anti-
proliferative activity against tumor cells (e.g., leukemia and
ovarian cancer cells) which are resistant to other microtubule-
targeted drugs (Armando et al., 2020). In addition to interfering
in microtubule function, albendazole seems to inhibit the produc-
tion of vascular endothelial growth factor (VEGF) and angiogenesis
in the peritoneal ovarian tumor in animal model (mice) (Armando
et al., 2020; Pourgholami, Cai, Lu, Wang, & Morris, 2006). Currently,
the anti-cancer effect of albendazole is being investigated in a
clinical trial (clinical trial no. NCT02366884) (Table 1).4.1.2. Ivermectin
Ivermectin exerts its anti-parasitic effects by increasing the par-
asite cell membrane permeability, resulting in paralysis and death.
It has also demonstrated some preliminary anti-cancer effects
(Armando et al., 2020). Ivermectin can inhibit proliferation, metas-
tasis, and angiogenic activity in various tumor and cancer cells.
These activities may result from its ability to regulate various sig-
naling pathways through p21-activated kinase 1. Also, ivermectin
helps programmed cell death, such as apoptosis, autophagy, and
pyroptosis. In addition, it is capable of sensitizing multidrug-
resistant cells to chemotherapeutics and causes an optimal effect
when used in combination with other chemotherapeutics (Tang
et al., 2020). Jiang et al. (Jiang, Wang, Sun, & Wu, 2019) demon-
strated that ivermectin was potent to reverse the resistance of
tumor cells to anti-cancer drugs. The drug functions mainly by
reducing the P-gp expression through the inhibition of the EGFR.
Ivermectin inhibits ERK/Akt/NF jB pathway through binding to
the extracellular domain of EGFR and inhibiting its activation.
The restriction of NF-jB causes a reduction of P-gp transcription.
Ivermectin also causes the restriction of yes associated protein 1
(YAP1), which functions as the transcription activator for those
genes related to cell proliferation and suppression of apoptosis
(Armando et al., 2020). Moreover, ivermectin blocks the karyo-
pherin b1 (KPNB1, encoding nuclear transport factors) function.
Fig. 1. Mode of action of albendazole (ABZ), ivermectin (IVM), levamisole (LV), mebendazole (MBZ), niclosamide (NIC), flubendazole (FLU), rafoxanide (RAF), nitazoxanide
(NTZ), pyrvinium pamoate (PP), and eprinomectin (EP).
Seyed Ebrahim Alavi and H. Ebrahimi Shahmabadi Saudi Pharmaceutical Journal 29 (2021) 434–445Kodama et al. (Kodama et al., 2017) demonstrated that ivermectin
inhibited the function of KPNB1 in ovarian cancer cells, resulting in
apoptosis and cell cycle arrest. Ivermectin, in combination with
paclitaxel, caused synergistic anti-cancer effects in vivo as well
(Kodama et al., 2017). Ivermectin can also inhibit the canonical
wnt (wingless-related integration site) signaling pathway that
influences a transcriptional factor of the T-cell factor (TCF) family,
resulting in the inhibition of colon and lung cancer proliferation
(Armando et al., 2020). Ivermectin is also able to modulate those
genes involved in the epithelial mesenchymal transition and
maintenance of a cancer stem cell (CSC) phenotype in triple-
negative breast cancer (TNBC), and consequently causes
dysfunction in clonogenic self renewal in vitro, and the restrictionTable 1
List of anthelmintics, which have demonstrated anti-cancer effects and are repositioning
Drug Phase Type of cancer
Albendazole II Colorectal cancer, le
ovarian cancers
Ivermectin II triple-negative breas
cancers
Levamisole III Hepatocellular carci
Levamisole III Intrahepatic cholang
Mebendazole III Colon cancer
Mebendazole Terminated (lack of effect) Gastrointestinal can
Mebendazole II Colorectal cancer
Niclosamide Terminated (low accrual) Colorectal cancer
Niclosamide II Colorectal cancer
Niclosamide II Familial adenomatou
Niclosamide II Tumors of neuroend
cancer (triple-negati
adrenocortical carcin
head and neck cance
438of tumor growth and metastasis in vivo (Kwon et al., 2015). In addi-
tion, ivermectin can cause anti-tumor effects through a variety of
mechanisms. It can interact with various targets, such as multidrug
resistance (MDR) protein (Juarez, Schcolnik-Cabrera, & Dueñas-
Gonzalez, 2018).
4.1.3. Levamisole
Levamisole has been identified with various functions, such as
anti-tumor activity (Qiao et al., 2020). In particular, it is used as
an adjuvant of 5-fluorouracil (5-FU) and in combination with 5-
FU for the treatment of colon cancer (stage III) (Qiao et al., 2020).
Costa e Silve et al. (Costa, Celani, Azevedo, & Medeiros, 2019) com-
pared the efficacy of levamisole with cisplatin in the treatment ofin oncology.
Study ID number
or reference
ukemia, liver and NCT02366884









ocrine origin, lung cancer (non small cell), breast
ve), acute myeloid leukemia, osteosarcoma,
oma, glioma tumors, ovarian, prostate, lung, and
rs
NCT02807805
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imaging. The results demonstrated that while the mean fluores-
cence intensity (MFI) was 245 ± 15 in the levamisole treated group,
this value was 277 ± 28 in the animals receiving cisplatin. The MFI
in the saline-treated group was 680 ± 57, which was considerably
higher than that in the other groups (p < 0.05). The results of the
study demonstrated that levamisole had a positive effect on the
treatment of urethane-induced lung tumors in rats (Costa et al.,
2019). Qiao et al. (Qiao et al., 2020) assessed the anti-cancer effects
of levamisole in lung cancer, both in vitro and in vivo, and the
results demonstrated that levamisole caused a reduction in the
proliferation of lung cancer cells and inhibited the cell cycle arrest
in G0/G1 phase. Also, levamisole caused an increase in the tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced
death receptor 4 (DR4)-independent apoptosis rate through the
restriction of the phosphorylation of c-Jun N-terminal kinase
(JNK). In addition, it was found that levamisole caused an increase
in the expression of LC3B (a component of LC3B-DR4/ErK as a cel-
lular protective pathway) and subsequently activated the phos-
phorylation of ErK and increased the DR4 expression. Currently,
levamisole has been evaluated in two clinical trials (phase III), in
terms of efficacy and safety. The first trial is evaluating the thera-
peutic effects of a levamisole in combination with arginine
hydrochloride in the patients, suffering from advanced hepatocel-
lular carcinoma (HCC) (NCT03950518). The second one is assessing
levamisole hydrochloride for the treatment advanced intrahepatic
cholangiocarcinoma (NCT03940378) (Laudisi et al., 2020).
4.1.4. Mebendazole
Mebendazole can be an appropriate repositioned drug as it has
a proper and proven toxicity profile and pharmacokinetics, making
the drug suitable for therapeutic purposes. Also, it is an inexpen-
sive drug that can be administered easily. Mebendazole causes
the inhibition of various factors contributing to tumor progressions
(e.g. polymerization of tubulin, angiogenesis, pro-survival path-
ways, and matrix metalloproteinases). Mebendazole causes direct
cytotoxic effects, has synergistic effects with ionizing radiations
and various chemotherapeutics, and motivates anti-tumoral
immune responses. Mebendazole, as a single agent or in combina-
tion with chemotherapeutics, causes a reduction or complete inhi-
bition of tumor growth, a significant decrease in the metastatic
spread, and an increase in survival time (Guerini et al., 2019).
The therapeutic effects of mebendazole against various cancers
have been demonstrated in various studies (X.-h. Chen et al.,
2019; L. Zhang et al., 2019. Chen et al. (X.-h. Chen et al., 2019)
demonstrated that mebendazole caused the induction of apoptosis
in c-Maf (a vital oncogenic transcription factor that participates in
myelomagenesis)-expressing myeloma cells. Also, an oral dose of
the drug caused a delay in the growth of human myeloma xeno-
grafts (nude mice) without inducing any evident toxicity. Zhang
et al. (L. Zhang et al., 2019) showed that mebendazole, at the con-
centration of 0.7 mM, was potent to inhibit the mammosphere for-
mation from non-sorted cells in two human breast cancer
SUM159PT and MDA-MB-231 cells by approximately 86 and 88%,
respectively, compared to the control group. At present, mebenda-
zole is in progress in various phases of clinical trials (II and III) for
the treatment of different cancers, including colon cancer and CRC
(NCT03925662).
4.1.5. Niclosamide
The mechanism of action of niclosamide against parasites com-
prises uncoupling the oxidative phosphorylation in mitochondria,
resulting in a disruption in the metabolism of parasites (Barbosa
et al., 2019). MacDonald et al. (MacDonald et al., 2006) may be
the first who identified the probable repositioning of niclosamide
for cancers when observed unexpected results for this drug. They439evaluated protein–protein interactions in human embryonic kid-
ney 293 (HEK-293) cells using protein-fragment complementation
assays (PCA) to detect hidden or not expected biological functions
from a wide variety of compounds, belonging to various therapeu-
tic categories. PCA can identify unexpected anti-proliferative
effects when using niclosamide, observed in various types of can-
cer cells, including a human prostate cancer cell (PC-3) (Samy
et al., 2020), a human lung cancer cell (A549) (Özdemir, Turanli,
Çaliskan, Arka, & Banoglu, 2020), a human pancreatic cancer cell
(MiaPaCa) (Lee, Lee, Sim, & Kim, 2020), a human colon cancer cell
(LOVO) (Lee et al., 2020), and a human glioblastoma cell (U87MG)
(Arzani et al., 2019), with an inhibitory concentration of 50 (IC50) at
the mean concentrations of 0.6 mM (MacDonald et al., 2006). Since
then, various preclinical studies (L. Chen, Wang, Shen, Lin, & Li,
2017; Suliman et al., 2016; Zhou, Jin, Jin, Liu, & Pan, 2017) demon-
strated that niclosamide exerts its anti-cancer effects through the
inhibition of signaling pathways, including NOTCH, NF-jB, and
mammalian target of rapamycin (mTOR). In addition, the potency
of the drug to inhibit other oncogenic pathways, such as Wnt/b-
catenin, STAT3, and MEK1/2-ERK1/2, has been demonstrated
against various types of cancer cells, such as esophageal, ovarian,
and melanoma, in several preclinical studies (Shangguan et al.,
2020; Wei, Liu, Yuan, & Yao, 2020; Zhu et al., 2019). Currently,
the anti-cancer effects of niclosamide have been evaluated in sev-
eral clinical trials (NCT02687009, NCT02519582, NCT04296851,
and NCT02807805).
4.2. Anthelmintics with promising anti-cancer effects
4.2.1. Flubendazole
Flubendazole has demonstrated anti-tumor effects against var-
ious cancer cells, including leukemia, neuroblastoma, multiple
myeloma, melanoma, and breast cancer cells (Armando et al.,
2020; Hou et al., 2015). It functions through i) the induction of
changes in microtubule structure, ii) the induction of apoptosis,
iii) the restriction of angiogenesis, iv) the induction of cell differen-
tiation, v) the restriction of cell migration, and vi) the induction of
reactive oxygen species (ROS) activating autophage (Armando
et al., 2020; Hou et al., 2015). Currently, there are no clinical trials
considering the anti-tumor effects of flubendazole against human
malignancies (Armando et al., 2020).
4.2.2. Rafoxanide
Rafoxanide is a halogenated salicylanilide and can effectively
inhibit the oncogenic BRAF V600E mutant protein, prevalently
developed in melanomas and CRCs, and linked with a poorer prog-
nosis (Laudisi et al., 2020). While it restricts the proliferation of
CRC cells, it has no effects on normal colonic epithelial cells. Rafox-
anide down-regulates the expression of cyclin D1 protein and
causes cell accumulation in the G0/G1 phase. These processes
depend upon the selective induction of the endoplasmic reticulum
stress response, resulting in caspase-dependent cell death (Grazia
et al., 2020). Also, it has been found that rafoxanide inhibits the
proliferation of human gastric cancer SGC-7901 and BGC-823 cells
in vitro via the restriction of the activity of the PI3K/Akt/mTOR sig-
naling pathway. This process induces autophagy and apoptosis in
cancerous cells (Liu et al., 2019).
4.2.3. Nitazoxanide
The anti-cancer effects of nitazoxanide have been reported
against various cancers, such as ovarian and colon cancers
(Laudisi et al., 2020; Pal, Nandave, & Kaithwas, 2020). Nitazoxanide
has exceptional pharmacokinetic and safety profiles. It can cause
CRC cells apoptosis in a glutathione-S-transferase P1 (GSTP1)-
dependent manner. In HCT-116 and HT-29-derived spheroids, nita-
zoxanide caused a reduction in c-Myc, mTOR, and Wnt signaling
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These findings were confirmed in vivo, where nitazoxanide
(100 mg/kg), in combination with irinotecan (40 mg/kg), induced
a strong suppression in the tumor growth of a human xenograft
colorectal cancer in NMRI nu/nu mice compared to irinotecan
alone (Laudisi et al., 2020). It has been demonstrated that, in breast
cancer xenograft mouse models, nitazoxanide functions through
various pathways, such as AMPK, mTOR, and Wnt signaling. Also,
in these models, nitazoxanide acts through the downregulation
of c-Myc (Pal et al., 2020). Pal et al. (Pal et al., 2020), in one study,
evaluated the anti-cancer effects of nitazoxanide (50 mg/kg) com-
pared to those of tamoxifen (tamoxifen) against mammary gland
carcinoma induced by N-methyl-N-nitrosourea (MNU) in experi-
mental rats. The results demonstrated that nitazoxanide restored
the histological architecture in the animals and caused a reduction
in the alveolar buds and a downregulation in the oxidative stress
markers, such as glutathione, protein carbonyl, and catalase, and
inflammatory markers, such as nitric oxide, hydrogen sulphide,
cyclooxygenase, and lipoxygenase. The results suggested that nita-
zoxanide could be exploited as a potential chemoprophylactic
agent against mammary gland carcinoma developed by MNU.
4.2.4. Praziquantel
Praziquantel is an anthelmintic drug, and its function has not
yet been well understood; however, it can function through the
blockage of Ca2+ channels, resulting in an increase in the intracel-
lular concentration of Ca2+ and the induction of muscular contrac-
tions (Laudisi et al., 2020). It has been demonstrated that
praziquantel at the concentration of 20–40 mM can increase the
cytotoxicity of paclitaxel. Especially, praziquantel in combination
with paclitaxel can synergistically inhibit cell proliferation and
causes apoptosis in various cancer cells, such as CRC DLD-1
(Laudisi et al., 2020). Praziquantel in combination with paclitaxel
is also able to impair the X-linked inhibitor of apoptosis protein
(XIAP) expression as an anti-apoptotic protein, that functions as
an effective inhibitor of caspase activity (Laudisi et al., 2020).
4.2.5. Pyrvinium pamoate
Pyrvinium pamoate is able to kill various cancer cells, especially
CSC. The drug functions through the reduction of WNT- and
Hedgehog-dependent signaling pathways (Dattilo et al., 2020). It
also causes an inhibition in the mitochondria respiration and can
inhibit oncogenic PI3K-dependent signaling (Dattilo et al., 2020).
Dattilo et al. (Dattilo et al., 2020) demonstrated the anti-cancer
effects of pyrvinium pamoate against triple-negative breast CSC
that caused a reduction in the metastases of CSC by affecting the
lipid anabolism. The drug caused a disruption in the anabolic flux
from glucose to cholesterol and fatty acids. Nair et al. (Nair et al.,
2020) evaluated the anti-cancer activity of pyrvinium pamoate
against human B cell acute lymphoblastic leukemia cells, including
REH and RS4. Also, the metabolic function of these cells was eval-
uated by measuring the rates of extracellular acidification and oxy-
gen consumption. The results demonstrated that pyrvinium
pamoate showed anti-leukemia effects against all cell lines with
the IC50 of 0.17 and 1 lM for REH and RS4 cells, respectively. Also,
the effects of the drug on the REH cell cycle were evaluated, and
the results demonstrated a significant reduction in the cell number
in the S (by ~26%) and M phases (by ~50%) compared to the control
group (Nair et al., 2020). The anti-tumor activity of pyrvinium
pamoate was also evaluated in a xenograft model of human pan-
creatic cancer PANC1 cells (Laudisi et al., 2020). The oral adminis-
tration of pyrvinium pamoate (100 and 200 mg) caused a reduction
in tumor growth and inhibited the Akt phosphorylation. It was
found that pyrvinium pamoate (0.1 and 0.3 mM) inhibited the tran-
scription of two critical chaperons (i.e. GRP78 and GRP94), thereby
restricted the unfolded protein response due to glucose depriva-440tion. The drug also inhibits other UPR pathways (e.g. XBP-1 and
ATF4) stimulated by glucose starvation (Laudisi et al., 2020).
4.2.6. Piperazine
The anti-cancer effects of piperazine and its derivatives against
various types of cancer cells have been demonstrated in various
studies (Evren, Yurttas, Eksellı, & Akalın-Cıftcı, 2019; Mongre
et al., 2019). The piperazine derivative AK301 at the concentration
of 5 mM could cause a critical impairment in the tubulin polymer-
ization and a mitotic arrest in human colorectal adenocarcinoma
HT-29 and HCT-116 cells (Laudisi et al., 2020). In parallel, AK301
induced the expression of tumor necrosis factor receptor 1 (TNFR1)
therefore caused an increase in the susceptibility of cancer cells to
apoptosis by TNF- a (Laudisi et al., 2020). Özdemir et al. (Özdemir
et al., 2020) developed a series of benzimidazole-piperazine
hybrids and evaluated their toxicity effects against human lung
cancer A549 and human breast cancer MCF-7 cells. The results
demonstrated that most of the hybrids had anti-proliferative activ-
ity against A549 cells with the IC50 of 2.8–7.8 mM. Also, one com-
pound demonstrated the most balanced cytotoxicity effect
towards A549 and MCF-7 cells with the IC50 of 5.4 and 4.2 mM,
respectively. Mechanistically, these compounds caused a cleavage
in PARP-1 and activate caspase 7, resulting in morphological
changes, such as bleb formation in the treated cells, and a signifi-
cant increase in the nuclear fragmentation. Considering all the
results, these findings demonstrate that these compounds
(benzimidazole-piperazine hybrids) exert their cytotoxicity
through the apoptotic cell death induction (Özdemir et al., 2020).
4.2.7. Eprinomectin
Eprinomectin is a member of avermectin drugs, demonstrating
exceptional broad-spectrum anti-parasitic activity. Samy et al.
(Samy et al., 2020) evaluated its anti-cancer effects against PC-3
cells. The results demonstrated that eprinomectin caused a signif-
icant reduction in PC-3 cell viability as well as suppression in col-
ony formation and wound healing abilities. Eprinomectin exerted
its cytotoxicity effects through inducing ROS and the activation
of apoptosis. The drug also could affect the cyclin-dependent
kinase 4 (CDK4), causing an arrest in the G0/G1 phase of the cell
cycle, resulting in the induction in PC-3 cells. Furthermore, epri-
nomectin could restrain the expression of various markers related
to cancer stem cells (e.g. ALDH1, Nanog, and CD44) and pluripotent
stem cells (e.g. alkaline phosphatase). In addition, it was found that
the drug caused the translocation of b-catenin from the nucleus to
the cytoplasm, resulting in the inhibition of Wnt/b-catenin signal-
ing pathway. In addition, the results of western blot analysis dis-
played that eprinomectin caused a reduction in the expression of
the crucial cell cycle (e.g. cyclin D3, and c-Myc) and anti-
apoptotic markers (e.g., Mcl-1, XIAP, c-IAP1, and survivin). In con-
trast, eprinomectin could activate pH2A.X, Bad, caspases 9, and 3. It
also caused a cleavage in PARP1. These findings demonstrated that
eprinomectin can be considered as a promising compound for the
treatment of advanced PCa cells through regulating apoptosis sig-
naling (Samy et al., 2020).5. Challenges with anthelmintics in cancer therapy
Low water solubility is a problem that limits the use of anthel-
mintics (P. Li, Rios Coronado, Longstaff, Tarashansky, & Wang,
2018). Drug insolubility can influence both the pharmacokinetic
and pharmacodynamic profiles of drugs. The low water solubility
of drugs can cause: i) a reduction in the drug absorption and per-
meation that in combination with the rapid drug degradation
could result in an inadequate in vivo drug concentration and failure
to achieve the therapeutic dose and thus the appropriate pharma-
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that results in the unforeseeable levels of bioavailability. To solve
these problems, the dosage forms can be increased; however,
increasing the dosage to achieve the therapeutic effects can result
in: i) an increase in the costs of treatment, ii) incomplete absorp-
tion of the drug in vivo and its removal from the environment,
and iii) the emergence of the drug toxicity (Khalikov & Dushkin,
2020). Therefore, the development of strategies to solve these
problems-related to anthelmintics is of great importance.6. Strategies to overcome these challenges
There are various shortcomings in the use of anthelmintics,
such as low water solubility and low bioavailability, resulting in
a reduction in the potency of these drugs for cancer therapy. To
overcome these challenges, various strategies could be suggested
as follow that enhance anti-cancer effects of anthelmintics.6.1. Nanoparticles for improving the solubility of anthelmintics
Nanoparticles are known with high surface to volume ratio,
meaning that by reducing the size, the higher surface area is pro-
vided (Barbosa et al., 2019). Increasing the surface area causes an
increase in the dissolution rate of the particles (Barbosa et al.,
2019). Also, nanoparticles take advantage of the ease of surface
modification, allowing them to target specific cancer cells, express-
ing specific surface receptors (Ghaferi, Asadollahzadeh,
Akbarzadeh, Ebrahimi Shahmabadi, & Alavi, 2020; Ghaferi, Koohi
Moftakhari Esfahani, et al., 2020) (Fig. 2A).
Particle size also impacts the diffusion layer thickness and sat-
uration solubility (Barbosa et al., 2019; Fontana et al., 2018;
Peltonen & Hirvonen, 2018). Increased saturation solubility and
dissolution rate are the two critical factors of nanoparticles to
enhance the drug absorption and bioavailability of the drugs with
poor water solubility (Barbosa et al., 2019). Using nanostructures
provides various advantages, such as i) drug protection from degra-
dation in the organism, ii) improved drug absorption in tumor tis-
sue, and iii) the modification of the drug pharmacokinetic
properties, compared to the free administration of the drugs
(Ebrahimi Shahmabadi et al., 2014; Ghaferi, Amari, et al., 2020;
Vieira & Gamarra, 2016). Also, drug encapsulation into nanoparti-
cles can improve the efficacy of the drug and reduce its side effects
(Alavi, Esfahani, Ghassemi, Akbarzadeh, & Hassanshahi, 2014;
Alavi, Muflih Al Harthi, Ebrahimi Shahmabadi, & Akbarzadeh,
2019). In addition, nanocarrier-based drug delivery systems cause
an increase in drug economic life (Movahedi, KOOHI, Alavi, &
Akbarzadeh, 2013). Researchers have used various nanocarriers
to improve the bioavailability of anthelmintics (Paredes, Llabot,
Sanchez Bruni, Allemandi, & Palma, 2016; Rehman, Khan, Khan,
Shafique, & Khan, 2018). Rehman et al. (Rehman et al., 2018) syn-
thesized niclosamide-loaded solid lipid nanoparticles (SLNs) and
could increase the bioavailability of the drug by 11.1-folds. This
finding indicated that the drug absorption significantly increased
by taking up SLNs, as a drug delivery system, from the gastroin-
testinal wall, resulting in an increase in the drug bioavailability.
Also, Paredes et al. (Paredes et al., 2016) synthesized self-
dispersible nanocrystals of albendazole and could increase the dis-
solution rate of the drug by 4-fold that could increase the drug
bioavailability. Nanocrystals have a very enlarged surface area,
which results in a rapid saturation in the dissolution layer around
the particles, and as a result an increase in the dissolution rate
(Paredes et al., 2016). In addition, Darwish et al. (Darwish,
Bayoumi, & El-Kolaly, 2018) synthesized nitazoxanide-loaded lipo-
some nanoparticles using the membrane extrusion method and
evaluated their biodistribution in ehrlich ascites carcinoma-441bearing swiss albino mice using gamma scintillation counter. The
results demonstrated a rapid and higher accumulation of the
nanoformulation in the tumor sites. This could result from the dis-
ruption of lipid bilayer due to the photosensitization process and
the singlet oxygen species as a result.
6.2. Pro-drug formulations
Prodrugs are chemically modified drug molecules that are inac-
tive or partially inactive. They are converted to the active parent
drug on or near the target site in vivo by chemical and/or enzy-
matic biotransformation to exert the therapeutic effects (Fig. 3).
The prodrug approach can resolve various unsuitable features,
such as poor aqueous solubility, poor oral or local absorption, short
half-life, and toxicity (Jornada et al., 2016). There are two major
classes of prodrugs, including carrier-linked prodrugs and biopre-
cursors (Jornada et al., 2016). Carrier-linked prodrugs are com-
posed of a drug linked to a promoiety, which is eliminated
through a chemical or enzymatic reaction, leading to the drug
release (Jubeh, Breijyeh, & Karaman, 2020), while bioprecursor pro-
drugs have no carrier and are quickly converted to an active drug
through oxidation or reduction reactions (Jornada et al., 2016;
Jubeh et al., 2020).
Prodrug design is a powerful tool to improve various properties
of drugs, such as solubility, and bioavailability(Sanches & Ferreira,
2019). Researchers, in various studies (Chassaing et al., 2008;
Flores-Ramos et al., 2017; L. Nielsen, Bundgaard, & Falch, 1992;
L. S. Nielsen, Sløk, & Bundgaard, 1994; Zimmermann et al., 2018),
have developed various prodrugs of anthelmintics to improve their
aqueous solubility. Nielsen et al. (L. Nielsen et al., 1992) synthe-
sized an N-(4-amino-methylbenzoyl)oxymethyl prodrug of thi-
abendazole, demonstrating a 300-fold higher water-solubility
compared to the parent compound. Nielsen et al. (L. S. Nielsen
et al., 1994), in another study, synthesized a prodrug of mebenda-
zole (N-alkoxycarbonyl), which was exceptionally more soluble
compared to mebendazole (solubility rate of 2.7  105 vs.
1.7  10-6 M for the prodrug and mebendazole, respectively). Chas-
saing et al. (Chassaing et al., 2008) synthesized a highly water-
soluble prodrug of fenbendazole, in which its aqueous solubility
was extraordinarily increased by 195-fold compared to when the
parent drug was used. Also, Flores-Ramos et al. (Flores-Ramos
et al., 2017) synthesized a phosphate salt prodrug of triclabenda-
zole (MFR-5) and demonstrated that its water solubility was
exceptionally increased by 88000-fold compared to that of the par-
ent compound. In addition, Zimmermann et al. (Zimmermann
et al., 2018) synthesized an N substituted prodrug of mebendazole,
and the results showed that the prodrug had more than 10000-fold
aqueous solubility compared to when mebendazole was used.
6.3. Production of solid dispersions
SDs strategy is a promising approach to improve drug solubility.
It is composed of two or more different components, including a
hydrophobic drug and a hydrophilic matrix (Fig. 4) (Khalikov &
Dushkin, 2020; Wagh & Wagh, 2015).
SDs of drugs are delivery systems for drug molecules and can
improve the biopharmaceutical properties of drugs, such as
increasing the solubility and bioavailability, decreasing the toxic-
ity, and increasing the stability of the drugs during storage. SDs
can increase the drug solubility through the following mecha-
nisms: i) decreasing the size of the particles, ii) improving the wet-
tability, and iii) increasing the level of drug dispersion in a
polymeric matrix (Khalikov & Dushkin, 2020). Various SDs, such
as disodium salt of glycyrrhizic acid (Na2GA) (Meteleva et al.,
2019), polyvinylpyrrolidone (Arkhipov et al., 2019), poloxamer
407 (Real, Orzan, Leonardi, & Salomon, 2020), polyethylene
Fig. 2. Using nanocarriers for improving drug solubility. A poor soluble drug can be loaded into a tumor cell-targeted nanocarrier and administered orally. The
nanoformulation is adsorbed through the gastrointestinal tract and deposited into the tumor tissue (e.g., liver tumor) through the Enhanced Permeation and Retention (EPR)
effect, resulting from the increased vascular permeability in the tumor tissue (passive mechanism). As the nanoformulation is targeted against tumor cells, it can specifically
interact with its specific receptor on the surface of tumor cells and internalized into the cells (active mechanism).
Fig. 3. Using prodrug for improving drug solubility to cross biological barriers. A) Due to low solubility, some drugs cannot cross biological barriers, and as a result, their
therapeutic effects cannot be observed or are decreased. B) This shortcoming can be resolved using the prodrug approach (carrier-linked prodrug), C) after crossing the
barrier, D) the prodrug is biotransformed, and the active drug is produced in the cell and demonstrates the optimized effect.
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Fig. 4. Solid dispersion (SD) approach is a successful method to improve the oral
absorption of poorly soluble drugs, such as anthelmintics. It can be prepared using
polymers and drugs. An SD formulation can be administered orally and absorbed
through the gastrointestinal tract, resulting in an increase in the blood concentra-
tions of the drugs.
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and povidone (M. Li et al., 2020), have been used to increase the
solubility of anthelmintics. Meteleva et al. (Meteleva et al., 2019)
provided an SD of praziquantel using Na2GA and could increase
the solubility of the drug by 3.5-folds. Also, Arkhipov et al.
(Arkhipov et al., 2019) prepared an SD of fenbendazole using
polyvinylpyrrolidone, and the results demonstrated an increase
in the drug solubility by 2.8-fold. In another study, Real et al.
(Real et al., 2020) provided an SD of triclabendazole using polox-
amer 407 that could increase the solubility of triclabendazole by
41.5-fold. In addition, Dong et al. (Dong et al., 2020) prepared an
SD of albendazole using PEG 6000/P 188 that increased the solubil-
ity of albendazole by 3.3-fold. Li et al. (M. Li et al., 2020), in the
other study, synthesized an SD of rafoxanide using povidone, and
the results showed an increase in the solubility of the drug by
7000-fold.7. Conclusion and future perspectives
The drug (approved and abandoned) repositioning is increas-
ingly used as a favorite and cost-effective strategy in oncology.
These drugs can reach the clinic more quickly as their safety and
pharmacological profiles have already been approved (Sleire
et al., 2017). Some of the anthelmintics have shown promising
results for cancer therapy. They can be administered as monother-
apy or in combination with other anti-cancer drugs to enhance the
anti-cancer effects in vitro and in preclinical studies. These drugs
have received considerable attention, as they can interfere with
key oncogenic pathways. These properties cause some anthelmin-
tics to be undergone clinical trials (phase II/III) for cancer treat-
ment (Laudisi et al., 2020). They are mainly administered orally,
resulting in their higher content in the gastrointestinal tract; how-
ever, their concentration in the circulation is usually very low
mainly due to low water solubility (Khalikov & Dushkin, 2020;
Laudisi et al., 2020). In this literature review, we discussed the
repositioning of anthelmintics in oncology, and the shortcomings
for their success to reach the clinic. As discussed, the main issue
that limits their use in vivo is low water solubility, resulting in their443low bioavailability. The strategies to overcome these shortcomings
(i.e., nanocarriers-based formulation, prodrug design, and SDs)
were also discussed. These strategies can be used to improve the
solubility, bioavailability, toxicity profile, and the cost-
effectiveness of anthelmintics in oncology. However, these need
to be optimized, in terms of toxicity profile and safety issues,
demanding further studies in future. Overall, the available data
have demonstrated that the repositioning of anthelmintics in can-
cer therapy is a promising approach and can be considered as a less
expensive and faster strategy for extending the repository of
approved drugs. However, to perform the repositioning, there are
some challenges that must be addressed to provide a real concep-
tion of whether a repositioning project is a valuable opportunity.
Consequently, further studies are required to better understand
the pharmacokinetic and dynamic profile of the upcoming formu-
lations in our body. In our opinion, the generation of effective for-
mulations of anthelmintics, as an anti-cancer, might require strong
interdisciplinary collaborations between chemists, material
scientists, and pharmacists. We hypothesize that listing those
anthelmintics that are currently under clinical trial or under inves-
tigation in research laboratories with their promising anti-cancer
effects as well as their challenges and potential strategies in one
place, in this review, will generate a greater interest in anthelmin-
tics and can help to formulate their anti-cancer effective formula-
tions soon.
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